(Q24243850)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

0 references

1 reference

title

Opioid antagonists for smoking cessation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

T Lancaster

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

L F Stead

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

A E Evins

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

18 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

CD003086

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

Naltrexone blockade of nicotine effects in cigarette smokers.

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Effect of naloxone on cigarette smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone alteration of acute smoking response in nicotine-dependent subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Role of naltrexone in initial smoking cessation: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone alteration of the nicotine-induced EEG and mood activation response in tobacco-deprived cigarette smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naloxone does not affect cigarette smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Correspondence of Interactive Voice Response (IVR) reports of nicotine withdrawal, craving, and negative mood with questionnaire ratings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Do daily interactive voice response reports of smoking behavior correspond with retrospective reports?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Smoke and mirrors: magnified beliefs that cigarette smoking suppresses weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Association of OPRM1 A118G variant with the relative reinforcing value of nicotine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone treatment for alcoholics: effect on cigarette smoking rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone, smoking behaviour and cigarette withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone administration affects ad libitum smoking behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

A randomized trial of naltrexone for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone augments the effects of nicotine replacement therapy in female smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone and nicotine patch smoking cessation: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Opiate antagonists reduce cocaine but not nicotine self-administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Antidepressants for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

The effect of bupropion on nicotine craving and withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Opioid antagonists for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

Buprenorphine effects on cigarette smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

7 January 2021

Naloxone precipitates nicotine abstinence syndrome in the rat

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

7 January 2021

Naloxone reduces cigarette smoking

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

7 January 2021

Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

7 January 2021

Naltrexone attenuates acute cigarette smoking behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

7 January 2021

High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

7 January 2021

Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

7 January 2021

Naltrexone effects on short-term and long-term smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003086.PUB2

7 January 2021

10.1002/14651858.CD003086.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054160%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference